Serious Adverse Event Reports To FDA Increase In 2003, CDER Report Says
Executive Summary
FDA's adverse event reporting system is capturing an increasing number of serious adverse events, according to data released by the agency May 25
You may also be interested in...
Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?
Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials